“I am excited to welcome Brent Dial, whose diverse and extensive experience will be a tremendous asset for PGDx as we manage our rapid growth, build our operations for commercial scale, and make strategic investments to bring precision medicine to more patients globally,” said Megan Bailey, Chief Executive Officer of PGDx. “Brent has established himself as an outstanding finance and strategic business leader across a number of organizations and is well suited to help lead our efforts to access growth capital to fuel our strategy. Importantly, he is strongly aligned with our corporate values and mission to empower the fight against cancer.”

Mr. Dial has led financial operations for multiple companies and holds experience in a number of relevant roles across sectors including technology, consumer & retail, and venture capital. Mr. Dial most recently was a Principal at Chordata Ventures, where he provided corporate finance advisory services and spent time as interim CFO for a number of portfolio companies. Previously, he was the Chief Financial Officer of Anheuser-Busch’s High End Beer business unit, where he closed over $500 million in acquisitions within the span of 30 months and implemented budgeting initiatives that delivered $63 million in cost savings. Mr. Dial has also led various strategic initiatives at J.P. Morgan Chase, Deutsche Bank Securities, and TCOM, L.P. He previously served in the United States Army for five years. Mr. Dial holds an MBA with a major in Corporate Finance from the University of Pennsylvania’s Wharton School and is a graduate of the United States Military Academy.

“I am thrilled to be joining PGDx, and excited by the innovative approach they have taken to advance next-generation sequencing products designed to expand access and bring the power of genomics closer to the patient,” said Dial. “The PGDx team shares my dedication to bold strategic thinking centered around a patient focused mission. I look forward to joining the team and will do my part to ensure we have the people, operations and investments needed to deliver on the promise of this technology.”

PGDx most recently launched elio™ plasma complete, an NGS kit solution for comprehensive blood-based genomic analysis. The company offers two additional pan-cancer kits, elio™ tissue complete and elio™ plasma resolve, which provide researchers and clinicians with the ability to identify biomarkers and profile tumors through advanced genomic sequencing within their own hospital systems and laboratories.

About Personal Genome Diagnostics

Personal Genome Diagnostics (PGDx) empowers the fight against cancer by unlocking actionable information from the genome. We are committed to improving clinical insight, speed of results, and healthcare economics by delivering a portfolio of regulated tissue-based and liquid biopsy genomic products for health systems worldwide. PGDx was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies. For additional information, visit www.pgdx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005111/en/